Objective: To investigate the genetic correlations between epithelial growth factor receptor (EGFR) mutation and FHIT methylation in patients diagnosed with lung adenocarcinoma (AC) and pulmonary tuberculosis (TB). Methods: The presence of EGFR mutations and the methylation status of the FHIT gene in patients presenting with AC and TB were analyzed. The correlation between TB status and the observed genetic and epigenetic variations was also examined. Results: Among the 90 patients included in the study, 38 exhibited EGFR mutations (14 among those with TB and 24 among those without TB), while 29 exhibited FHIT myelination (19 among those with TB and 10 among those without TB). Furthermore, the protein expression levels of EGFR and FHIT were significantly higher in patients diagnosed solely with AC compared to those presenting with both AC and TB. A robust inverse correlation was identified between TB status and the frequency of EGFR mutation (P < 0.001). Moreover, significant associations were observed between TB status and FHIT methylation (P < 0.01). Conclusion: The findings suggest a correlation between TB and the prevalence of EGFR mutation and FHIT methylation in the pathogenesis of AC.
Thandra KC, Barsouk A, Saginala K, et al., 2021 Epidemiology of Lung Cancer. Contemp Oncol (Pozn), 25(1): 45–52. https://doi.org/10.5114/wo.2021.103829
Casal-Mouriño A, Ruano-Ravina A, Lorenzo-González M, et al., 2021, Epidemiology of Stage III Lung Cancer: Frequency, Diagnostic Characteristics, and Survival. Transl Lung Cancer Res, 10(1): 506–518. https://doi.org/10.21037/tlcr.2020.03.40
Drapkin BJ, Rudin CM, 2021, Advances in Small-Cell Lung Cancer (SCLC) Translational Research. Cold Spring Harb Perspect Med, 11(4): a038240. https://doi.org/10.1101/cshperspect.a038240
Wu F, Wang L, Zhou C, 2021, Lung Cancer in China: Current and Prospect. Curr Opin Oncol, 33(1): 40–46. https://doi.org/10.1097/CCO.0000000000000703
Rodak O, Peris-Díaz MD, Olbromski M, et al., 2021, Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. Cancers (Basel), 13(18): 4705. https://doi.org/10.3390/cancers13184705
Abdeahad H, Salehi M, Yaghoubi A, et al., 2022, Previous Pulmonary Tuberculosis Enhances the Risk of Lung Cancer: Systematic Reviews and Meta-Analysis. Infect Dis (Lond), 54(4): 255–268. https://doi.org/10.1080/23744235.2021.2006772
Cabrera-Sanchez J, Cuba V, Vega V, et al., 2022, Lung Cancer Occurrence After an Episode of Tuberculosis: A Systematic Review and Meta-Analysis. Eur Respir Rev, 31(165): 220025. https://doi.org/10.1183/16000617.0025-2022
Li L, Ye Z, Yang S, et al., 2021, Diagnosis of Pulmonary Nodules by DNA Methylation Analysis in Bronchoalveolar Lavage Fluids. Clin Epigenetics, 13(1): 185. https://doi.org/10.1186/s13148-021-01163-w
Malhotra J, Malvezzi M, Negri E, et al., 2016, Risk Factors for Lung Cancer Worldwide. Eur Respir J, 48(3): 889–902. https://doi.org/10.1183/13993003.00359-2016
Sun YQ, Richmond RC, Suderman M, et al., 2021, Assessing the Role of Genome-Wide DNA Methylation Between Smoking and Risk of Lung Cancer Using Repeated Measurements: The HUNT Study. Int J Epidemiol, 50(5): 1482–1497. https://doi.org/10.1093/ije/dyab044
Joshi A, Butle A, Hait S, et al., 2022, Osimertinib for Lung Cancer Cells Harboring Low-Frequency EGFR T790M Mutation. Transl Oncol, 22: 101461. https://doi.org/10.1016/j.tranon.2022.101461
Yanagawa N, Tamura G, Oizumi H, et al., 2002, Frequent Epigenetic Silencing of the p16 Gene in Non-Small Cell Lung Cancers of Smokers. Jpn J Cancer Res, 93(10): 1107–1113. https://doi.org/10.1111/j.1349-7006.2002.tb01212.x
Yanagawa N, Tamura G, Oizumi H, et al., 2007, Promoter Hypermethylation of RASSF1A and RUNX3 Genes as an Independent Prognostic Prediction Marker in Surgically Resected Non-Small Cell Lung Cancers. Lung Cancer, 58(1): 131–138. https://doi.org/10.1016/j.lungcan.2007.05.011
Luo YH, Wu CH, Wu WS, et al., 2012, Association between Tumor Epidermal Growth Factor Receptor Mutation and Pulmonary Tuberculosis in Patients with Adenocarcinoma of the Lungs. J Thorac Oncol, 7(2): 299–305. https://doi.org/10.1097/JTO.0b013e31823c588d
Chang C-H, Lee C-H, Ho C-C, et al., 2015, Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients with Nonsmall Cell Lung Cancer and Previous Tuberculosis. Medicine (Baltimore), 94(4): e444. https://doi.org/10.1097/MD.0000000000000444
Bobak CA, Natarajan H, Gandhi T, et al., 2022, Increased DNA Methylation, Cellular Senescence and Premature Epigenetic Aging in Guinea Pigs and Humans with Tuberculosis. Aging (Albany NY), 14(5): 2174–2193. https://doi.org/10.18632/aging.203936
Kwon MH, Lee GE, Kwon SJ, et al., 2008, Identification of DNA Methylation Markers for NSCLC Using Hpall-Mspl Methylation Microarray. Tuberc Respir Dis, 65(6): 495–503. https://doi.org/10.4046/trd.2008.65.6.495
Sharma G, Sowpati DT, Singh P, et al., 2016, Genome-Wide Non-CpG Methylation of the Host Genome During M. tuberculosis Infection. Sci Rep, 6: 25006. https://doi.org/10.1038/srep25006
Shell SS, Prestwich EG, Baek SH, et al., 2013, DNA Methylation Impacts Gene Expression and Ensures Hypoxic Survival of Mycobacterium tuberculosis. PLoS Pathog, 9(7): e1003419. https://doi.org/10.1371/journal.ppat.1003419
Zheng L, Leung ETY, Wong HK, et al., 2016, Unraveling Methylation Changes of Host Macrophages in Mycobacterium tuberculosis Infection. Tuberculosis (Edinb), 98: 139–148. https://doi.org/10.1016/j.tube.2016.03.003
Nishihara S, Yamaoka T, Ishikawa F, et al., 2022, Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer. Genes (Basel), 13(12): 2183. https://doi.org/10.3390/genes13122183
Yamaoka T, Arata S, Homma M, et al., 2019, Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury. Int J Mol Sci, 20(16): 4021. https://doi.org/10.3390/ijms20164021
Talukdar S, Emdad L, Das SK, et al., 2020, EGFR: An Essential Receptor Tyrosine Kinase-Regulator of Cancer Stem Cells. Adv Cancer Res, 147: 161–188. https://doi.org/10.1016/bs.acr.2020.04.003
Moriya T, Hamaji M, Yoshizawa A, et al., 2022, Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors as a First-Line Treatment for Postoperative Recurrent and EGFR-Mutated Non-Small-Cell Lung Cancer. Interact Cardiovasc Thorac Surg, 34(3): 416–423. https://doi.org/10.1093/icvts/ivab283
Zhou J, Yu X, Hou L, et al., 2021, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Remodels Tumor Microenvironment by Upregulating LAG-3 in Advanced Non-Small-Cell Lung Cancer. Lung Cancer, 153: 143–149. https://doi.org/10.1016/j.lungcan.2021.01.010
Passaro A, Mok T, Peters S, et al., 2021, Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC with Uncommon, Non Exon 20 Insertions, EGFR Mutations. J Thorac Oncol, 16(5): 764–773. https://doi.org/10.1016/j.jtho.2020.12.002
Chang Q, Qiang H, Qian J, et al., 2021, Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study. Front Oncol, 11: 652560. https://doi.org/10.3389/fonc.2021.652560
Yang Z, Hackshaw A, Feng Q, et al., 2017, Comparison of Gefitinib, Erlotinib and Afatinib in Non-Small Cell Lung Cancer: A Meta-Analysis. Int J Cancer, 140(12): 2805–2819. https://doi.org/10.1002/ijc.30691
Normanno N, De Luca A, Bianco C, et al., 2006, Epidermal Growth Factor Receptor (EGFR) Signaling in Cancer. Gene, 366(1): 2–16. https://doi.org/10.1016/j.gene.2005.10.018
Ortiz AFH, Garland ME, Almarie B, 2022, Clinical and Radiological Characteristics to Differentiate Between EGFR Exon 21 and Exon 19 Mutations in Patients with Lung Adenocarcinoma: A Systematic Literature Review and Meta-Analysis. Cureus, 14(5): e25446. https://doi.org/10.7759/cureus.25446